Can we learn from what a patient's tumour is telling us in terms of what the immune system is responding to in order to target it therapeutically?
Highlights from SITC 2019 including small cap biotechs with novel or innovative approaches to consider
Analysis and commentary of Nektar's IL-2 cytokine bempeg in combination with nivolumab in 1L advanced melanoma
If we want to improve on the current results with IO therapies then we need to go to basics and understand the biology of each disease subset in the context of what we've learned so far
What's hot at SITC19 this year? We highlight half a dozen key presentations of interest to BSB readers and explain why they matter.
What new things will we learn about the microbiome at SITC19?
